General discussion, page-17212

I'm sure some others would be interested in your explanation on how strong the patent is and why the drag on these assets being monetized?

Regular news on an anti opioid alternative would be very exciting, so why has the company chosen to hold back?

What did you tell me about silence again?

Re your question, not as confident in IHL as I once was. Hope I'm wrong for the many good people on here.

I can't work out why the IHL 42 trial has taken so long to progress albeit it's moving now.

It was white hot but that seems like such a long time ago.

It's not like money was an issue.

For potential buyers, maybe these drags in progress are an issue.

It's not like the executive aren't being paid enough.

The consultancy fees and lofty bonuses may be perceived as red flags, too.

Shareholders are hurting so how do they justify these excesses?

Consultancy for exactly what? Bonus for hitting exactly what KPIs out of the park.

The actual wage is already very much on the high side.

Dr Sud apparently thinks all these other things you talk about aren't worth as much as you do, or he wouldn't have sold so many.

Wouldn't he know the inside workings of this executive better than anyone?

IMO & GLTA